Literature DB >> 28795281

Selective A2A receptor antagonist SCH 58261 modulates striatal oxidative stress and alleviates toxicity induced by 3-Nitropropionic acid in male Wistar rats.

Cristiani F Bortolatto1, Angélica S Reis2, Mikaela P Pinz2, Guilherme T Voss2, Renata L Oliveira2, Ane G Vogt2, Silvane Roman3, Cristiano R Jesse4, Cristiane Luchese2, Ethel A Wilhelm5.   

Abstract

The aim of the present study was to investigate the effects of SCH58261, a selective adenosine A2A receptor antagonist, on striatal toxicity induced by 3-nitropropionic acid (3-NP) in rats. The experimental protocol consisted of 10 administrations (once a day) of SCH58261 (0.01 or 0.05 mg/kg/day, intraperitoneal, i.p.). From 7th to 10th day, 3-NP (20 mg/kg/day, i.p.) was injected 1 h after SCH58261 administration. Twenty-four hours after the last 3-NP injection, the body weight gain, locomotor activity (open-field test), motor coordination (rotarod test), striatal succinate dehydrogenase (SDH) activity and parameters linked to striatal oxidative status were evaluated in rats. The marked body weight loss resulting from 3-NP injections in rats was partially protected by SCH 58261 at both doses. SCH 58261 at the highest dose was effective against impairments on motor coordination and locomotor activity induced by 3-NP. SCH 58261 was unable to restore the inhibition of SDH activity caused by 3-NP. In addition, the increase in striatal reactive species (RS) levels, depletion of reduced glutathione (GSH) content and stimulation of glutathione reductase (GR) activity provoked by 3-NP injections were alleviated by both doses of SCH 58261. The highest dose of SCH 58261 was also effective in attenuating the increase of protein carbonyl levels as well as the inhibition of glutathione peroxidase (GPx) activity in rats exposed to 3-NP. Our results revealed that reduction of oxidative stress in rat striatum by adenosine A2A receptor antagonism contributes for alleviating 3-NP-induced toxicity.

Entities:  

Keywords:  3-nitropropionic acid; Adenosine A2A receptor; Oxidative stress; SCH 58261; Toxicity

Mesh:

Substances:

Year:  2017        PMID: 28795281     DOI: 10.1007/s11011-017-0086-1

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  37 in total

1.  Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.

Authors:  Patrizia Popoli; Annita Pintor; Maria Rosaria Domenici; Claudio Frank; Maria Teresa Tebano; Antonella Pèzzola; Laura Scarchilli; Davide Quarta; Rosaria Reggio; Fiorella Malchiodi-Albedi; Mario Falchi; Marino Massotti
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

Review 2.  The role of glutathione in brain tumor drug resistance.

Authors:  Donald S Backos; Christopher C Franklin; Philip Reigan
Journal:  Biochem Pharmacol       Date:  2011-11-28       Impact factor: 5.858

3.  Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin.

Authors:  Alexandra Benchoua; Yaël Trioulier; Diana Zala; Marie-Claude Gaillard; Nathalie Lefort; Noelle Dufour; Frederic Saudou; Jean-Marc Elalouf; Etienne Hirsch; Philippe Hantraye; Nicole Déglon; Emmanuel Brouillet
Journal:  Mol Biol Cell       Date:  2006-02-01       Impact factor: 4.138

4.  Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.

Authors:  Shilpa Ramaswamy; Jodi L McBride; Christopher D Herzog; Eugene Brandon; Mehdi Gasmi; Raymond T Bartus; Jeffrey H Kordower
Journal:  Neurobiol Dis       Date:  2007-01-25       Impact factor: 5.996

Review 5.  Stem cell-based therapy for Huntington's disease.

Authors:  Christof Maucksch; Elena M Vazey; Renee J Gordon; Bronwen Connor
Journal:  J Cell Biochem       Date:  2013-04       Impact factor: 4.429

Review 6.  Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Mol Cell Neurosci       Date:  2012-12-05       Impact factor: 4.314

Review 7.  Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence.

Authors:  C Allison; J A Pratt
Journal:  Pharmacol Ther       Date:  2003-05       Impact factor: 12.310

8.  Proteomic and oxidative stress analysis in human brain samples of Huntington disease.

Authors:  Ma Alba Sorolla; Gemma Reverter-Branchat; Jordi Tamarit; Isidre Ferrer; Joaquim Ros; Elisa Cabiscol
Journal:  Free Radic Biol Med       Date:  2008-05-28       Impact factor: 7.376

9.  8OHdG as a marker for Huntington disease progression.

Authors:  Jeffrey D Long; Wayne R Matson; Andrew R Juhl; Blair R Leavitt; Jane S Paulsen
Journal:  Neurobiol Dis       Date:  2012-03-05       Impact factor: 5.996

10.  A new drug design targeting the adenosinergic system for Huntington's disease.

Authors:  Nai-Kuei Huang; Jung-Hsin Lin; Jiun-Tsai Lin; Chia-I Lin; Eric Minwei Liu; Chun-Jung Lin; Wan-Ping Chen; Yuh-Chiang Shen; Hui-Mei Chen; Jhih-Bin Chen; Hsing-Lin Lai; Chieh-Wen Yang; Ming-Chang Chiang; Yu-Shuo Wu; Chen Chang; Jiang-Fan Chen; Jim-Min Fang; Yun-Lian Lin; Yijuang Chern
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

View more
  1 in total

Review 1.  Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.

Authors:  Melissa Talita Wiprich; Carla Denise Bonan
Journal:  Front Neurosci       Date:  2021-07-01       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.